Amgen Inc. $AMGN Shares Bought by Quadrant Capital Group LLC

Quadrant Capital Group LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 11.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,133 shares of the medical research company’s stock after acquiring an additional 1,569 shares during the quarter. Quadrant Capital Group LLC’s holdings in Amgen were worth $4,225,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in AMGN. Vinva Investment Management Ltd raised its stake in shares of Amgen by 33.0% during the second quarter. Vinva Investment Management Ltd now owns 36,950 shares of the medical research company’s stock valued at $10,240,000 after purchasing an additional 9,178 shares during the period. Wambolt & Associates LLC purchased a new position in Amgen in the second quarter valued at about $236,000. Choreo LLC boosted its stake in shares of Amgen by 1.4% during the 2nd quarter. Choreo LLC now owns 18,456 shares of the medical research company’s stock valued at $5,153,000 after buying an additional 250 shares during the last quarter. Inceptionr LLC grew its holdings in Amgen by 5.3% during the 2nd quarter. Inceptionr LLC now owns 4,210 shares of the medical research company’s stock worth $1,175,000 after acquiring an additional 212 shares in the last quarter. Finally, J.W. Cole Advisors Inc. lifted its position in shares of Amgen by 107.7% during the second quarter. J.W. Cole Advisors Inc. now owns 24,003 shares of the medical research company’s stock worth $6,702,000 after purchasing an additional 12,447 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on AMGN. The Goldman Sachs Group reiterated a “buy” rating on shares of Amgen in a research report on Tuesday. Deutsche Bank Aktiengesellschaft increased their target price on shares of Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a report on Tuesday, November 11th. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. HSBC lifted their target price on Amgen from $343.00 to $381.00 and gave the company a “buy” rating in a research note on Wednesday, November 19th. Finally, Truist Financial initiated coverage on Amgen in a research report on Monday. They set a “hold” rating and a $318.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $333.74.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This represents a 11.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 over the last ninety days. Insiders own 0.76% of the company’s stock.

Amgen Trading Up 1.0%

Amgen stock opened at $344.57 on Thursday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $345.84. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The stock has a market capitalization of $185.54 billion, a PE ratio of 28.17, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. The firm has a 50 day simple moving average of $304.95 and a 200-day simple moving average of $293.90.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. During the same period in the prior year, the firm posted $5.58 earnings per share. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, November 21st. Amgen’s payout ratio is presently 73.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.